NCT07602855
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07602855
Title A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Acronym EMBOLD PanTumour-103
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
GSK Investigational Site RECRUITING Los Angeles California 90027 United States Details
GSK Investigational Site RECRUITING Wilson North Carolina 27893-3484 United States Details
GSK Investigational Site RECRUITING Canton Ohio 44718 United States Details
GSK Investigational Site RECRUITING Osaka 573-1191 Japan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field